申请人:Alcon Research, Ltd.
公开号:EP2481741A1
公开(公告)日:2012-08-01
The invention is directed to substantially pure fluorescein, substantially pure fluorescein compositions and to pharmaceutical compositions for use in angiography. A substantially pure fluorescein is provided which is low in colour, low in sodium chloride content, and substantially free of pyridine. Fluorescein comprised in the composition is defmed as substantially pure if there are no detectable fluorescein-related substance impurities, or if a single fluorescein-related substance impurity is detected, it is present in an amount no greater than 0.1 % by weight, or if multiple fluorescein-related substance impurities are detected, they are present in aggregate in an amount no greater than 0.6% by weight, and wherein said fluorescein-related substance impurities comprise; synthetic impurities arising from the reaction of resorcinol with succinic acid (as an impurity in the phthalic acid precursor for fluorescein); isomers, oxidation products, dimerization products, and decomposition products of fluorescein.
本发明涉及用于血管造影术的基本纯荧光素、基本纯荧光素组合物和药物组合物。本发明提供了一种色度低、氯化钠含量低且基本不含吡啶的高纯度荧光素。如果不存在可检测到的荧光素相关物质杂质,或如果检测到单个荧光素相关物质杂质,其含量不超过 0.1%(按重量计),或如果检测到多个荧光素相关物质杂质,其总含量不超过 0.6% (按重量计),其中所述荧光素相关物质杂质包括;间苯二酚与琥珀酸反应产生的合成杂质(作为荧光素邻苯二甲酸前体中的杂质);荧光素的异构体、氧化产物、二聚化产物和分解产物。